PharmiWeb.com - Global Pharma News & Resources
01-Apr-2019

4SC AG: Dynavax's SD-101 and 4SC's Domatinostat Demonstrate Synergy and Induce a Systemic Anti-tumor Response in Preclinical Models

DGAP-News: 4SC AG / Key word(s): Scientific publication


The issuer is solely responsible for the content of this announcement.




01.04.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: 4SC AG
Fraunhoferstr. 22
82152 Planegg-Martinsried
Germany
Phone: +49 89 700763-0
Fax: +49 89 700763-29
E-mail: public@4sc.com
Internet: www.4sc.com
ISIN: DE000A14KL72
WKN: A14KL7
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 793575

 
End of News DGAP News Service

Editor Details

Last Updated: 01-Apr-2019